Zorevunersen

Stoke Therapeutics is accelerating its Dravet syndrome drug development, aiming for a mid-2027 NDA submission for zorevunersen. The company is collaborating with Biogen on this RNA medicine designed to address the root cause of the severe epilepsy by restoring a key protein. Positive Phase 3 enrollment is on track, and Stoke is actively engaging with the FDA to expedite the drug’s availability for patients with limited options. The company has sufficient funding to support operations through 2028.